The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The importance of myeloma-specific frailty indices in trial design
Ashley Rosko, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses recent advancements in the management of older adults with multiple myeloma (MM), emphasizing the shift from age-based to frailty-based clinical trials. Dr Rosko highlights the importance of myeloma-specific frailty indices in trial design, which allow for more tailored treatment strategies based on patients’ physiological health. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
